Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine

Bellanti, Joseph A.; Zeligs, Barbara J.; Mendez-Inocencio, Julia; García-García, Ma. de Lourdes; Islas-Romero, Rocío; Omidvar, Berna; Omidvar, Jemal; Kim, Gino; Castro, J Fernández de; Amor, Jaime Sepúlveda; Walls, Laura; Bellini, William J.; Valdespino-Gómez, José Luis

doi:10.1016/j.vaccine.2003.09.032

Cited by 48 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The seroresponse to aerosolized measles component of the MMR II vaccine (44%), was higher than that obtained in another study where adults (18 -25 years of age) received the aerosolized Triviraten vaccine (Berna Biotech ® ) containing the EZ measles virus (30%) and also higher than adults of the same study who received injections of MMR II (19%) or Triviraten vaccine (6%) [3,4]. Booster doses by aerosol of EZ measles vaccine, whether given as M, MR, or MMR, have consistently proved more immunogenic than the same vaccine given by injection [1][2][3]6,[17][18][19]. The above positive findings, despite very high baseline titers to measles, suggest this may also prove true for Attenuvax (Schwarz) measles vaccine.…”

Section: Discussionmentioning

confidence: 99%

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

Díaz-Ortega¹,

Bennett²,

Castaneda³

et al. 2012

WJV

Self Cite

View full text Add to dashboard Cite

Background: There have been no reported studies involving aerosol immunization with 2 of the 3 components of MMR II vaccine-Attenuvax measles vaccine and Jeryl-Lyn mumps vaccine. Objective: To evaluate the safety and antibody responses to aerosolized Attenuvax measles strain, Jeryl Lynn mumps strain and RA 27/3 rubella component of an MMR vaccine in adults, before assessing the booster administration of this vaccine in children. Methods: A pilot study to evaluate safety and antibody responses of MMR II (Merch Sharp & Dhome Corp., Whitehouse Station, NJ 08889, USA) components administered by aerosol was carried out in 27 healthy adults of 21 to 38 years of age. All participants were followed-up during 28 days following immunization for detection of clinical adverse events. Immune response was evaluated by plaque reduction neutralization test for measles, and commercial ELISA kits for rubella and mumps. Results: Only mild clinical adverse events were noted. Despite high levels of baseline seropositivity to all vaccine components, seroresponses to measles, rubella and mumps occurred in 44%, 15% and 41%, respectively. Conclusions: These outcomes compare favorably with earlier studies of other MMR vaccines given by aerosol. Further evaluations on safety and booster immune response should be performed in children.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

Díaz-Ortega¹,

Bennett²,

Castaneda³

et al. 2012

WJV

Self Cite

View full text Add to dashboard Cite

show abstract

“…on May 9, 2018 by guest http://cvi.asm.org/ impact by diminishing virus excretion and transmission to susceptible individuals. Bellanti et al reported significantly higher levels of measles virus-specific IgA and IgG in serum and nasal secretions in response to a live attenuated measles vaccine administered by aerosol than in response to s.c. immunization (3). Although the correlate of protection against measles is serum PRN antibody (5), with the understanding that virus-neutralizing antibodies can block cell invasion, additional mechanisms may also be involved in protection.…”

Section: Discussionmentioning

confidence: 99%

“…This strategy includes immunization using alternative routes of vaccine delivery, such as smallparticle aerosol and large-droplet intranasal administration (6). The small-particle aerosol route is currently favored, as it has been shown to induce strong and long-lived systemic and mucosal immune responses (3,7,8).…”

mentioning

confidence: 99%

Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine

Simon

Ramírez

Cuberos

et al. 2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Measles remains an important cause of morbidity and mortality among children in the developing world. The goal of this study was to examine measles virus-specific mucosal immune responses in healthy immune (n ‫؍‬ 24; plaque reduction neutralization [PRN] titers of >200 mIU/ml) and nonimmune (n ‫؍‬ 24) young adult volunteers who received the monovalent Moraten measles vaccine via intranasal (spray delivery) or subcutaneous immunization. Serum, oral fluid, and nasal wash samples were examined for measles virus-specific and total IgG and IgA on day 0 (prior to vaccination) and on days 14, 28, and 90 after vaccination. Nonimmune subjects vaccinated subcutaneously developed high levels of measles virus PRN, IgG, and IgA antibodies in serum, oral fluid, and nasal washes. Total IgG and secretory IgA (sIgA) titers were increased in nasal washes, and total IgG was increased in oral fluid specimens. There was a strong correlation between PRN and measles virus-specific IgG titers measured in serum, oral fluid, and nasal washes, whereas a weak correlation was found between PRN and measles virus-specific IgA titers. Notably, intranasal measles vaccination resulted in increased production of measles virus-specific sIgA in oral fluid and nasal washes in nonimmune individuals, without evidence of a systemic immune response. In contrast, no significant vaccine-induced responses were observed in immune subjects, regardless of the route of immunization. These results demonstrate that (i) intranasal measles immunization can elicit a mucosal response independent of the induction of serum antibodies and (ii) both mucosal and systemic antibody responses following nasal or subcutaneous immunization are blunted by preexisting measles immunity.

show abstract

“…Seroconversion was affected by baseline neutralization antibody titers, being higher among children with lowest baseline titers. As to infants, data indicate that the vaccine administered as primary immunization is immunogenic but that viral concentration will probably need [24,25] 92% (92%) [41] 76% (53-100) [16,19,28,42] to be increased. These studies have indicated that potency of the vaccine will probably need to be at least 10 4.5 pfu when administered as primary dose to infants or as booster dose to children with baseline antibody titers (Table 3).…”

Section: Discussionmentioning

confidence: 99%

“…Serum and nasal IgG and IgA antibody responses were stimulated by either route but these responses were significantly greater by the aerosol compared to the subcutaneous route. These studies also suggested that the measurement of mucosal immune responses may serve as an important predictive marker of protective immunity to measles and lent support for aerosol immunization as an effective alternative vaccine delivery strategy for measles eradication [42].…”

Section: Recent Mexican Studiesmentioning

confidence: 91%

Measles Aerosol Vaccination

Valdespino-Gómez¹,

García-García

Fernandez-de-Castro

et al. 2006

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine

Cited by 48 publications

References 19 publications

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine

Measles Aerosol Vaccination

Contact Info

Product

Resources

About